person · Reporting owner

NOHRA GUY P

Disclosed activity across 4 companies

Tapewire entity: 39204
SEC CIK: 0001198330

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allakos Inc.ALLK · Entity 79644	10% owner	March 04, 2021	March 09, 2021
Bioventus Inc.BVS · Entity 4996	Director	June 02, 2026	June 04, 2026
TELA Bio, Inc.TELA · Entity 7381	Director	June 09, 2026	June 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allakos Inc.

Report date March 04, 2021 · Filed March 09, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,468	Reported balance After 2021-03-04 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-03-04 · Sale · Disposed 2,300 · Balance 23,468 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.375 - $109.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F4: Shares held prior to the reported transaction consisted of an aggregate of 25,768 shares received in pro rata distributions from Alta Partners NextGen Fund I L.P. and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.
Common StockSEC Table I · non-derivative	Direct	19,457	Reported balance After 2021-03-04 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2021-03-04 · Sale · Disposed 4,011 · Balance 19,457 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.39 - $110.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	Direct	16,315	Reported balance After 2021-03-04 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2021-03-04 · Sale · Disposed 3,142 · Balance 16,315 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.41 - $111.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	Direct	10,429	Reported balance After 2021-03-04 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2021-03-04 · Sale · Disposed 5,886 · Balance 10,429 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.42 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	Direct	1,126	Reported balance After 2021-03-04 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2021-03-04 · Sale · Disposed 9,303 · Balance 1,126 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.445 - $113.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-03-04 transaction · row 7 Account or security details depend on footnotes; rows are not merged. 1 source row Row 7 · 2021-03-04 · Sale · Disposed 1,126 · Balance 0 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.44 - $114.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,448,053	Reported balance Holding disclosure · report date 2021-03-04 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,448,053 F1: Reflects a distribution in kind effected by Alta Partners VIII, L.P. ("Alta VIII") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16. F2: These shares are directly held by Alta VIII. Alta Partners Management VIII, LLC ("Alta Management VIII") is the general partner of Alta VIII. The Reporting Person is a managing director of Alta Management VIII and, as such, may be deemed to share voting and investment control with respect to the shares held by Alta VIII. The Reporting Person disclaims beneficial ownership of all shares held by Alta VIII, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a distribution in kind effected by Alta Partners VIII, L.P. ("Alta VIII") subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16.

F2: These shares are directly held by Alta VIII. Alta Partners Management VIII, LLC ("Alta Management VIII") is the general partner of Alta VIII. The Reporting Person is a managing director of Alta Management VIII and, as such, may be deemed to share voting and investment control with respect to the shares held by Alta VIII. The Reporting Person disclaims beneficial ownership of all shares held by Alta VIII, except to the extent of his pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.375 - $109.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F4: Shares held prior to the reported transaction consisted of an aggregate of 25,768 shares received in pro rata distributions from Alta Partners NextGen Fund I L.P. and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.39 - $110.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.41 - $111.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.42 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.445 - $113.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.44 - $114.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Bioventus Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	148,892	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 148,892
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	25,146	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

F2: The RSUs vested on June 2, 2026.

F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

TELA Bio, Inc.

Report date June 09, 2026 · Filed June 11, 2026

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SUTRO BIOPHARMA, INC.

Report date October 01, 2018 · Filed October 01, 2018

Jointly reported with Alta Partners VIII, L.P., Alta Partners Management VIII, LLC, CHAMPSI FARAH, JANNEY DANIEL

Section 16 reporting ended · disclosed 2018-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,944,901	Last balance in matching sequence After 2018-10-01 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2018-10-01 · Conversion · Acquired 589,661 · Balance 589,661 F1: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Row 2 · 2018-10-01 · Conversion · Acquired 458,331 · Balance 1,047,992 F3: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Row 3 · 2018-10-01 · Conversion · Acquired 382,698 · Balance 1,430,690 F4: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Row 4 · 2018-10-01 · Conversion · Acquired 514,211 · Balance 1,944,901 F5: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-10-01 · Conversion · Disposed 10,201,769 · Balance 0 F1: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-10-01 · Conversion · Disposed 12,387,324 · Balance 0 F3: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
Series D Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-10-01 · Conversion · Disposed 9,449,318 · Balance 0 F4: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
Series E Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-10-01 · Conversion · Disposed 18,698,578 · Balance 0 F5: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F2: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.

F3: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F5: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 11, 2026 22:04 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantStock Option (Right to Buy) · Derivative	17,335	$0.00 Strike: $0.94	$0.00	Disclosure SEC source: 0001198330-26-000007 · form4-06112026_100610.xml · derivative · entry 4 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,335 Underlying: Common Stock · 17,335 shares Expires 2036-06-09 F4 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:04 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantStock Option (Right to Buy) · Derivative	17,550	$0.00 Strike: $0.94	$0.00	Disclosure SEC source: 0001198330-26-000007 · form4-06112026_100610.xml · derivative · entry 3 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2036-06-09 F3 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:04 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantCommon Stock	11,675	$0.00	$0.00	Disclosure SEC source: 0001198330-26-000007 · form4-06112026_100610.xml · nonDerivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,600 F2 · shares: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:04 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantCommon Stock	11,925	$0.00	$0.00	Disclosure SEC source: 0001198330-26-000007 · form4-06112026_100610.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,925 F1 · shares: These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 03, 2026 Filed Jun 4, 2026 20:47 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	25,146	$0.00	$0.00	Disclosure SEC source: 0001198330-26-000002 · wk-form4_1780606051.xml · derivative · entry 3 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 02, 2026 Filed Jun 4, 2026 20:47 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	32,282	$0.00	$0.00	Disclosure SEC source: 0001198330-26-000002 · wk-form4_1780606051.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document
June 02, 2026 Filed Jun 4, 2026 20:47 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	32,282	$0.00	$0.00	Disclosure SEC source: 0001198330-26-000002 · wk-form4_1780606051.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2025 Filed Dec 8, 2025 22:02 UTC	Bioventus Inc. BVS · Entity 4996	SaleClass A Common Stock	10,000	$7.57	$75,658.00	Disclosure SEC source: 0001198330-25-000003 · wk-form4_1765231346.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,610 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.56 to $7.60, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
June 03, 2025 Filed Jun 5, 2025 01:30 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	32,282	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000308 · wk-form4_1749087024.xml · derivative · entry 3 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 02, 2025 Filed Jun 5, 2025 01:30 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000308 · wk-form4_1749087024.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document
June 02, 2025 Filed Jun 5, 2025 01:30 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-25-000308 · wk-form4_1749087024.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2024 Filed Jun 13, 2024 21:27 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	26,493	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000289 · wk-form4_1718314059.xml · derivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 07, 2024 Filed Jun 12, 2024 00:46 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000270 · wk-form4_1718153176.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document
June 07, 2024 Filed Jun 12, 2024 00:46 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000270 · wk-form4_1718153176.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 16, 2023 Filed Aug 19, 2023 00:08 UTC	Bioventus Inc. BVS · Entity 4996	OtherClass A Common Stock	41,369	$0.00	$0.00	Disclosure SEC source: 0001209191-23-046658 · doc4.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,717 F1 · kind: Represents the receipt of shares pursuant to a pro rata in-kind distribution of common stock of the Issuer by Alta Partners Management VIII, LLC, without consideration, to its members, including the Reporting Person in connection with the winding down of the operations of Alta Partners VIII, L.P. Read SEC document
August 16, 2023 Filed Aug 23, 2023 21:56 UTC Amendment	Bioventus Inc. BVS · Entity 4996	OtherClass A Common Stock	2,604,264	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000075 · primary_doc.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Represents a pro rata in-kind distribution of common stock of the Issuer by Alta Partners Management VIII, LLC, without consideration, to its members, including the Reporting Person in connection with the winding down of the operations of Alta Partners VIII, L.P. F2 · ownership.nature: The reported shares are held by Alta Partners VIII, L.P. Alta Partners Management VIII, LLC is the general partner of Alta Partners VIII, L.P. The Reporting Person is one of the managing directors and a member of Alta Partners Management VIII, LLC and shares voting and dispositive power with respect to the shares held by Alta Partners VIII, L.P. The Reporting Person disclaims beneficial ownership of the shares reported herein except to the extent of his proportionate pecuniary interest therein. Read SEC document
June 07, 2023 Filed Jun 8, 2023 23:42 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	30,400	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000042 · primary_doc.xml · derivative · entry 3 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F2 · derivative.exercise_price: The RSUs vested on June 6, 2023. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 23:42 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	16,648	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000042 · primary_doc.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 23:42 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	16,648	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000042 · primary_doc.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2022 Filed Jun 23, 2022 00:44 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	16,648	$0.00	$0.00	Disclosure SEC source: 0000899243-22-023649 · doc4.xml · derivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document
April 01, 2022 Filed Apr 6, 2022 01:12 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	2,700	$0.00	$0.00	Disclosure SEC source: 0000899243-22-013958 · doc4.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on April 1, 2022. F2 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document
April 01, 2022 Filed Apr 6, 2022 01:12 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	2,700	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-013958 · doc4.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document
February 11, 2022 Filed Feb 16, 2022 02:33 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionRestricted Stock Units · Derivative	9,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-006551 · doc4.xml · derivative · entry 2 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document
February 11, 2022 Filed Feb 16, 2022 02:33 UTC	Bioventus Inc. BVS · Entity 4996	Exercise / conversionClass A Common Stock	9,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-006551 · doc4.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document
April 01, 2021 Filed Apr 5, 2021 20:32 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	2,700	$0.00	$0.00	Disclosure SEC source: 0000899243-21-014834 · doc4.xml · derivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	1,126	$113.57	$127,879.82	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 7 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.44 - $114.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	9,303	$113.01	$1,051,332.03	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 6 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.445 - $113.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	5,886	$111.80	$658,054.80	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 5 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,429 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.42 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	3,142	$110.84	$348,259.28	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 4 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,315 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.41 - $111.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	4,011	$109.89	$440,768.79	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 3 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,457 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.39 - $110.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 04, 2021 Filed Mar 9, 2021 01:40 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	2,300	$108.89	$250,447.00	Disclosure SEC source: 0001209191-21-018789 · doc4.xml · nonDerivative · entry 2 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,468 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.375 - $109.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F4 · balance_after: Shares held prior to the reported transaction consisted of an aggregate of 25,768 shares received in pro rata distributions from Alta Partners NextGen Fund I L.P. and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16. Read SEC document
February 11, 2021 Filed Feb 16, 2021 23:06 UTC	Bioventus Inc. BVS · Entity 4996	GrantRestricted Stock Units · Derivative	9,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006740 · doc4.xml · derivative · entry 1 NOHRA GUY P · CIK 0001198330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document
June 17, 2020 Filed Jun 19, 2020 23:24 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	606	$77.21	$46,789.26	Disclosure SEC source: 0001209191-20-038071 · doc4.xml · nonDerivative · entry 3 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.15 - $77.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
June 17, 2020 Filed Jun 19, 2020 23:24 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	1,414	$76.52	$108,199.28	Disclosure SEC source: 0001209191-20-038071 · doc4.xml · nonDerivative · entry 2 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.11 - $77.095, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
June 17, 2020 Filed Jun 19, 2020 23:24 UTC	Allakos Inc. ALLK · Entity 79644	SaleCommon Stock	5,672	$75.23	$426,704.56	Disclosure SEC source: 0001209191-20-038071 · doc4.xml · nonDerivative · entry 1 NOHRA GUY P · CIK 0001198330 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,020 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 - $75.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	6,837	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 7 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 F9 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein. F9 · ownership.direct: Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	11,539	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 6 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alta Bioequities, L.P. Disclosed balance after: 11,539 F8 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F8 · ownership.nature: Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	11,538	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 5 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hudson Capital LLC Disclosed balance after: 11,538 F7 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F7 · ownership.nature: Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	11,538	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 4 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 F6 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein. F6 · ownership.direct: Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	34,615	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 3 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By APNG I Management Disclosed balance after: 0 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by APNG I Management, without consideration, to its members. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	34,615	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 2 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By APNG I Management Disclosed balance after: 34,615 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. ("APNG I"), without consideration, to its general partner and limited partners. Read SEC document
January 22, 2020 Filed Jan 24, 2020 18:24 UTC	Allakos Inc. ALLK · Entity 79644	OtherCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004922 · doc4.xml · nonDerivative · entry 1 Alta Partners NextGen Fund I Management, LLC · CIK 0001736001 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner Alta Partners NextGen Fund I, L.P. · CIK 0001698110 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner MORE ROBERT J · CIK 0001207792 · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,519,200 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. ("APNG I"), without consideration, to its general partner and limited partners. F2 · ownership.nature: Consists of 2,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta Partners VIII, L.P. ("Alta VIII"). F3 · ownership.nature: The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their respective pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries E Preferred Stock · Derivative	18,698,578	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · derivative · entry 8 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 514,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries D Preferred Stock · Derivative	9,449,318	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · derivative · entry 7 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 382,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	12,387,324	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · derivative · entry 6 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458,331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries B Preferred Stock · Derivative	10,201,769	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · derivative · entry 5 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 589,661 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	514,211	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · nonDerivative · entry 4 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,944,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	382,698	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · nonDerivative · entry 3 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	458,331	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · nonDerivative · entry 2 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,047,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:12 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	589,661	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052831 · doc4.xml · nonDerivative · entry 1 Alta Partners VIII, L.P. · CIK 0001399763 · 10% owner Alta Partners Management VIII, LLC · CIK 0001399894 · 10% owner CHAMPSI FARAH · CIK 0001198321 · 10% owner JANNEY DANIEL · CIK 0001198325 · Director · 10% owner NOHRA GUY P · CIK 0001198330 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.